JAMIE WHITESELL: Open Payments
NPI 1336690163 · BROOMALL, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$616 in 36 payments from 9 companies in 2025. Trend: 2023 $90 · 2024 $535 · 2025 $616
Food & beverage: $616
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 18 | $272 |
| Novo Nordisk Inc | 5 | $110 |
| ABBVIE INC. | 4 | $71 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| Novartis Pharmaceuticals Corporation | 2 | $31 |
| Ardelyx, Inc. | 1 | $26 |
| Exeltis, USA Inc. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: AIRSUPRA, UBRELVY, Wegovy, KESIMPTA, IBSRELA, Yeztugo, SLYND, Adzenys XR-ODT.
Industry payments across PA — which companies pay providers there.
